|
显示项目 651276-651300 / 2303271 (共92131页)
<< < 26047 26048 26049 26050 26051 26052 26053 26054 26055 26056 > >>
每页显示[10|25|50]项目
| 國立臺灣大學 |
2012 |
Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.
|
Yalcin, Suayib; Buyukberber, Suleyman; Yilmaz, Ugur; Lee, Po-Huang; Srimuninnimit, Vichien; Lin, Pin-Wen; Elserafy, Mostafa M.; Manieh, Moustafa; Sunpaweravong, Patrapim; Istomin, Yuriy; Sriuranpong, Virote; Hwang, Tsann-Long; 李伯皇 |
| 國家衛生研究院 |
2018-01 |
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
|
Javle, M;Lowery, M;Shroff, RT;Weiss, KH;Springfeld, C;Borad, MJ;Ramanathan, RK;Goyal, L;Sadeghi, S;Macarulla, T;El-Khoueiry, A;Kelley, RK;Borbath, I;Choo, SP;Oh, DY;Philip, PA;Chen, LT;Reungwetwattana, T;Van Cutsem, E;Yeh, KH;Ciombor, K;Finn, RS;Patel, A;Sen, S;Porter, D;Isaacs, R;Zhu, AX;Abou-Alfa, GK;Bekaii-Saab, T |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma
|
Javle M.;Lowery M.;Shroff R.T.;Weiss K.H.;Springfeld C.;Borad M.J.;Ramanathan R.K.;Goyal L.;Sadeghi S.;Macarulla T.;El-Khoueiry A.;Kelley R.K.;Borbath I.;Choo S.P.;Oh D.-Y.;Philip P.A.;Chen L.-T.;Reungwetwattana T.;Van Cutsem E.;Kun-Huei Yeh;Ciombor K.;Finn R.S.;Patel A.;Sen S.;Porter D.;Isaacs R.;Zhu A.X.;Abou-Alfa G.K.;Bekaii-Saab T.; Javle M.; Lowery M.; Shroff R.T.; Weiss K.H.; Springfeld C.; Borad M.J.; Ramanathan R.K.; Goyal L.; Sadeghi S.; Macarulla T.; El-Khoueiry A.; Kelley R.K.; Borbath I.; Choo S.P.; Oh D.-Y.; Philip P.A.; Chen L.-T.; Reungwetwattana T.; Van Cutsem E.; KUN-HUEI YEH; Ciombor K.; Finn R.S.; Patel A.; Sen S.; Porter D.; Isaacs R.; Zhu A.X.; Abou-Alfa G.K.; Bekaii-Saab T. |
| 國立成功大學 |
2018 |
Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma
|
Javle, M.;Lowery, M.;Shroff, R.T.;Weiss, K.H.;Springfeld, C.;Borad, M.J.;Ramanathan, Ramanathan R.K.;Goyal, L.;Sadeghi, Sadeghi S.;Macarulla, T.;El-Khoueiry, A.;Kelley, R.K.;Borbath, I.;Choo, S.P.;Oh, D.-Y.;Philip, Philip P.A.;Chen, L.-T.;Reungwetwattana, T.;Van, Cutsem E.;Yeh, K.-H.;Ciombor, K.;Finn, R.S.;Patel, A.;Sen, Sen S.;Porter, D.;Isaacs, R.;Zhu, A.X.;Abou-Alfa, G.K.;Bekaii-Saab, T. |
| 國家衛生研究院 |
2009-11 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang, HJ;Huang, CL;Wang, HP;Shiah, HS;Chang, MC;Jan, CM;Chen, JS;Tien, YW;Hwang, TL;Lin, JT;Cheng, AL;Whang-Peng, J;Chen, LT |
| 國立成功大學 |
2009-11 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang, Hui-Ju; Huang, Chin-Lun; Wang, Hsiu-Po; Shiah, Her-Shyong; Chang, Ming-Chu; Jan, Chang-Ming; Chen, Jen-Shi; Tien, Yu-Wen; Hwang, Tsann-Long; Lin, Jaw-Town; Cheng, Ann-Lii; Whang-Peng, Jacqueline; Chen, Li-Tzong |
| 國立臺灣大學 |
2009 |
Phase Ii Study of Biweekly Gemcitabine Followed by Oxaliplatin and Simplified 48-H Infusion of 5-Fluorouracil/Leucovorin (Gofl) in Advanced Pancreatic Cancer
|
常慧如; 黃敬倫; 王秀伯; 夏和雄; 章明珠; 詹昌明; 陳仁熙; 田郁文; 黃燦龍; 林肇堂; 鄭安理; 彭汪嘉康; 陳立宗; CHANG, HUI-JU; HUANG, CHING-LUN; WANG, HSIU-PO; SHIAH, HER-SHYONG; CHANG, MING-CHU; JAN, CHANG-MING; CHEN, JEN-SHI; TIEN, YU-WEN; HWANG, TSANN-LONG; LIN, JAW-TOWN; CHENG, ANN-LII; WHANG-PENG, JACQUELINE; CHEN, LI-TZONG |
| 臺大學術典藏 |
2018-09-10T07:26:16Z |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang, H.-J. and Huang, C.-L. and Wang, H.-P. and Shiah, H.-S. and Chang, M.-C. and Jan, C.-M. and Chen, J.-S. and Tien, Y.-W. and Hwang, T.-L. and Lin, J.-T. and Cheng, A.-L. and Whang-Peng, J. and Chen, L.-T.; YU-WEN TIEN; ANN-LII CHENG |
| 臺大學術典藏 |
2020-02-20T06:53:15Z |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang H.-J.; Shiah H.-S.; Chang M.-C.; Jan C.-M.; Chen J.-S.; YU-WEN TIEN; Hwang T.-L.; Lin J.-T.; Cheng A.-L.; Whang-Peng J.; Chen L.-T.; Wang H.-P.; Huang C.-L. |
| 臺大學術典藏 |
2021-09-01T01:54:18Z |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang H.-J.; Huang C.-L.; Wang H.-P.; Shiah H.-S.; Chang M.-C.; Jan C.-M.; Chen J.-S.; Tien Y.-W.; Hwang T.-L.; Lin J.-T.; ANN-LII CHENG; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-15T03:47:10Z |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang H.-J.; Huang C.-L.; HSIU-PO WANG; Shiah H.-S.; Chang M.-C.; Jan C.-M.; Chen J.-S.; Tien Y.-W.; Hwang T.-L.; Lin J.-T.; Cheng A.-L.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-03-05T06:07:26Z |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
|
Ch'ang H.-J.; Huang C.-L.; Wang H.-P.; Shiah H.-S.; MING-CHU CHANG; Jan C.-M.; Chen J.-S.; Tien Y.-W.; Hwang T.-L.; Lin J.-T.; Cheng A.-L.; Whang-Peng J.; Chen L.-T. |
| 國立臺灣大學 |
2009-11 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer. Cancer Chemother Pharmacol.
|
Chang, HJ; Huang, CL; Wang, HP; Shiah, HS; Chang, MC; Jan, CM; Chen, JS; Tien, YW; Hwang, TL; Lin, JT; Cheng, AL; Whang-Peng, J; Chen, LT. |
| 臺大學術典藏 |
2020-11-27T08:14:19Z |
Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer
|
CHANG-YAO HSIEH; Sukthomya V.; Lertsanguansinchai P.; Kamnerdsupaphon P.; Tharavichitkul E.; Phromratanapongse P.; Chitapanarux I.; Lorvidhaya V.; Lorvidhaya V.;Chitapanarux I.;Phromratanapongse P.;Kamnerdsupaphon P.;Tharavichitkul E.;Lertsanguansinchai P.;Chang-Yao Hsieh;Sukthomya V. |
| 國立臺灣大學 |
2009 |
Phase Ii Study of Cetuximab Plus Weekly Cisplatin and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin for the First-Line Treatment of Advanced Gastric Cancer
|
葉坤輝; 徐志宏; 許駿; 林璟宏; 沈盈君; 邱宗傑; 趙毅; 鄭安理; YEH, KUN-HUEI; HSU, CHIH-HUNG; HSU, CHIUN; LIN, CHING-HUNG; SHEN, YING-CHUN; CHIOU, TZEON-JYE; CHAO, YEE; CHENG, ANN-LII |
| 國立臺灣大學 |
2004 |
Phase Ii Study of Combination Doxorubicin, Interferon-Alpha, and High- Dose Tamoxifen Treatment for Advanced Hepatocellular Carcinoma
|
盧彥伸; 許駿; 李啟誠; 郭頌鑫; 葉坤輝; 楊志新; 徐志宏; 吳貞瑤; 鄭安理; LU, YEN-SHEN; HSU, CHIUN; LI, CHI-CHENG; KUO, SUNG-HSIN; YEH, KUN-HUEI; YANG, CHIH-HSIN; HSU, CHIH-HUNG; WU, CHEN-YAO; CHENG, ANN-LII |
| 國立臺灣大學 |
2004-05 |
Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
|
Lu, YS; Hsu, C; Li, CC; Kuo, SH; Kun-Huei, Yeh; Yang, CH; Hsu, CH; Wu, CY; Cheng, AL. |
| 臺大學術典藏 |
2018-09-10T04:46:19Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu, Y.-S. and Hsu, C. and Li, C.-C. and Kuo, S.-H. and Yeh, K.-H. and Yang, C.-H. and Hsu, C.-H. and Wu, C.-Y. and Cheng, A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
CHIH-HUNG HSU; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Chih-Hung Hsu;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S;Hsu C;Li C.-C;Kuo S.-H;Yeh K.-H;Chih-Hsin Yang;Hsu C.-H;Wu C.-Y;Cheng A.-L.; Lu Y.-S; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; CHIH-HSIN YANG; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Kun-Huei Yeh;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T02:02:21Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Cheng A.-L.;Wu C.-Y;Hsu C.-H;Yang C.-H;Yeh K.-H;Kuo S.-H;Li C.-C;Hsu C;Yen-Shen Lu; YEN-SHEN LU; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:44Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Sung-Hsin Kuo;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; SUNG-HSIN KUO; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
显示项目 651276-651300 / 2303271 (共92131页)
<< < 26047 26048 26049 26050 26051 26052 26053 26054 26055 26056 > >>
每页显示[10|25|50]项目
|
